Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 23.78 as of 2026-10-03T00:15:29.228Z.
Consensus retrieved: 2026-10-02T23:00:42.891Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-03T00:15:29.228Z.
Quote observation: 2026-10-02T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 05a8d9fc23beb7e9946354f3630d8b432f7666156d0c15d473c0a61afd7aee29
Forward PE Ratio (23.78) = Dated Quote Price ($20.00) / Consensus Forward EPS ($0.84)
FORWARD PE RATIO
23.78
SECTOR MEDIAN · HEALTHCARE
18.80
median of 81 covered companies
CURRENT VS SECTOR MEDIAN
+26.49%
vs the sector median at left
Fortrea Holdings Inc.
Market Cap
$1.90B
Forward PE Ratio
23.78
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Fortrea Holdings Inc. (FTRE) | $1.90B | 23.78 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 5.68 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 54.40 |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 101.08 |
| NRC Health (NRC)vs › | $458.62M | 23.13 |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
23.8
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $20.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.84 | $0.78 – $0.99 | 7 | 23.8x |
| 2027-12-31 | $1.06 | $0.88 – $1.28 | 7 | 18.8x |
| 2028-12-31 | $1.33 | $-31.18 – $39.14 | 4 | 15.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
